PubMed Health⌕ Search

PubMed · 10092382

Ionic Diffusivity, Electrical Conductivity, Membrane and Thermoelectric Potentials in Colloids and Granular Porous Media: A Unified Model.

Abstract

Ionic diffusivity, electrical conductivity, membrane and thermoelectric potentials in isotropic and homogeneous colloidal suspensions, and granular porous media saturated by a binary symmetric 1:1 electrolyte are four interrelated phenomena. The microstructure and the surface properties of the solid grains-water interface influence directly these properties. The ionic diffusivities (and the electrical conductivity, respectively) in colloids and porous media have contributions from diffusion (and electromigration, respectively) through the bulk solution occupying the pores, together with electromigration occurring at the grains-water interface in the electrical double layer. Surface diffusion in porous materials has no contribution from concentration gradients along the grains-water interface. Instead, surface diffusion is envisioned as a purely electromigration process due to the membrane potential. The tortuosities of the transport of anions and cations are equal to the bulk tortuosity of the pore space only at high ionic strength. As the ionic strength decreases, the dominant paths for transport of the ion corresponding to the counterion of the electrical double layer shift from the pore space to the solid grains-water interface. Because anions and cations do not move independently, the membrane potential created by the charge polarization alters the velocity of the anions and influences the mutual diffusivity coefficient of the salt in the porous material. An electric potential of thermal origin is also produced in nonisothermal conditions. The ionic contributions to the electrical conductivity are based on a differential effective medium approach. These ionic contributions to the electrical conductivity are used to derive the ionic diffusivities and the membrane and thermoelectric potentials. The influence of the temperature and the presence, in the pore space, of a second immiscible and nonwetting phase is also considered in this model. Porosity is shown to affect the membrane potential. Several predictions of the model are checked with success by comparing the model to a set of experimental data previously published. Copyright 1999 Academic Press.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Revil. 1999-04-15. Ionic Diffusivity, Electrical Conductivity, Membrane and Thermoelectric Potentials in Colloids and Granular Porous Media: A Unified Model.. https://doi.org/10.1006/jcis.1998.6077

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗